Maze Therapeutics (NASDAQ:MAZE) Price Target Raised to $58.00 at Wedbush

Maze Therapeutics (NASDAQ:MAZE) had its target price raised by Wedbush from $43.00 to $58.00 in a research report report published on Monday,Benzinga reports. Wedbush currently has an outperform rating on the stock.

Several other analysts also recently issued reports on the company. Lifesci Capital raised Maze Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Wells Fargo & Company started coverage on Maze Therapeutics in a research note on Thursday, December 4th. They set an “overweight” rating and a $55.00 price objective for the company. Mizuho upgraded Maze Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 11th. Guggenheim boosted their price target on shares of Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Finally, Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 7th. Two investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $57.38.

Maze Therapeutics Stock Up 2.1%

Shares of MAZE stock opened at $51.26 on Monday. The company has a market cap of $2.47 billion, a P/E ratio of -2.45 and a beta of 4.46. The business has a 50 day moving average of $45.07 and a two-hundred day moving average of $36.16. Maze Therapeutics has a 52 week low of $6.71 and a 52 week high of $53.65.

Insider Buying and Selling

In other Maze Therapeutics news, SVP Amy Bachrodt sold 10,000 shares of the business’s stock in a transaction on Monday, December 29th. The stock was sold at an average price of $40.58, for a total transaction of $405,800.00. Following the completion of the transaction, the senior vice president owned 12,965 shares in the company, valued at approximately $526,119.70. The trade was a 43.54% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Atul Dandekar sold 72,400 shares of the business’s stock in a transaction on Monday, December 29th. The stock was sold at an average price of $40.56, for a total value of $2,936,544.00. Following the transaction, the insider owned 10,503 shares of the company’s stock, valued at $426,001.68. This trade represents a 87.33% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 230,000 shares of company stock valued at $9,768,292 in the last three months.

Institutional Investors Weigh In On Maze Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Royal Bank of Canada lifted its holdings in Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares during the period. Ameritas Investment Partners Inc. increased its stake in Maze Therapeutics by 82.6% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares during the period. California State Teachers Retirement System increased its stake in Maze Therapeutics by 138.0% during the 4th quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock valued at $55,000 after buying an additional 766 shares during the period. Police & Firemen s Retirement System of New Jersey raised its position in shares of Maze Therapeutics by 18.5% during the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company’s stock worth $247,000 after buying an additional 931 shares in the last quarter. Finally, GF Fund Management CO. LTD. bought a new stake in shares of Maze Therapeutics during the 4th quarter worth about $39,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.